Partnering with scientists to accelerate transformation in cancer research

Our Mission


The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. We fulfill our mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and early-stage companies in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding basic and translational cancer research that bridges the gap between bench and bedside through grants and venture investments.

latest news


The Mark Foundation for Cancer Research Launches Drug Discovery Partnerships

Read More

The Mark Foundation Launches Inaugural Industry Advisory Committee

Read More

Over $1 Million Awarded to MD Anderson Cancer Center for Transformative Translational Research

Read More

Collaboration Launched with Cancer Research Institute to Evaluate Liquid Biopsy

Read More
View all news

Our Grant Portfolio


128 Grants

Over $100 Million Awarded


  • 61% Translational Science
  • 9% Technology Innovation
  • 20% Basic Research
  • 8% Therapeutic Discovery
  • 2% Clinical

Funding By Cancer Type


  • 55% All cancer types
  • 5% Others
  • 5% Leukemia
  • 4% Brain Tumors
  • 1% Melanoma
  • 14% Breast Cancer
  • 4% Pancreatic Cancer
  • 1% Colorectal Cancer
  • 8% Lung Cancer
  • 1% Lymphoma
  • 1% Ovarian Cancer
  • 1% Prostate Cancer

Over 60 Institutions

In 6 Countries


  • CANADA
  • NETHERLANDS
  • DENMARK
  • UNITED KINGDOM
  • FRANCE
  • USA